# Empagliflozin + Linagliptin

## Glyxambi 25/5mg

| TAH Drug Code      | [OGXB](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OGXB)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Indicated for improving blood sugar control in the following patients with type 2 diabetes in conjunction with diet and exercise: those who have not achieved adequate blood sugar control with the combination of metformin and empagliflozin or linagliptin， or those already receiving combination therapy with empagliflozin and linagliptin. Empagliflozin， when used in adults with type 2 diabetes who have cardiovascular disease， can reduce the risk of cardiovascular death. However， the effectiveness of this medication in reducing the risk of cardiovascular death in adults with type 2 diabetes and cardiovascular disease has not been established for this product. |
| Dosing             | Initial empagliflozin 10 mg/linagliptin 5 mg orally once daily in the morning， may increase to empagliflozin 25 mg/linagliptin 5 mg once daily if tolerated.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Patients with severe renal impairment， end-stage renal disease， or those receiving dialysis. Patients who have had a severe allergic reaction to empagliflozin， linagliptin， or any excipient in GLYXAMBI， such as acute allergy， angioedema， desquamation， urticaria， or a history of bronchial allergy.                                                                                                                                                                                                                                                                                                                                                                          |
| Adverse Effects    | Common Renal: Urinary tract infectious disease (11.4% to 12.5% ) Respiratory: Nasopharyngitis (5.9% to 6.6% )， Upper respiratory infection (7% ) Serious Cardiovascular: Heart failure， Hypotension Endocrine metabolic: Diabetic ketoacidosis， Hypoglycemia (2.2% to 3.6% ) Gastrointestinal: Pancreatitis Immunologic: Hypersensitivity reaction Musculoskeletal: Arthralgia Renal: Creatinine clearance-glomerular filtration abnormal， Decreased， Pyelonephritis， Sepsis due to urinary tract infection， Serum creatinine raised Reproductive: Necrotizing fasciitis， Perineum Other: Angioedema                                                                                |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/empagliflozin-and-linagliptin-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

